20 citations
,
February 2023 in “American Journal of Clinical Dermatology” In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.
2 citations
,
March 2026 in “Journal of Dermatological Treatment” This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.
September 2024 in “Journal of the American Academy of Dermatology” In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.
14 citations
,
January 2017 in “Skin appendage disorders” This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.
August 2025 in “Ophthalmic Plastic and Reconstructive Surgery” In this case report, a 4-year-old with neurofibromatosis type 1 experienced significant reduction in an inoperable periorbital plexiform neurofibroma and visual improvement following treatment with selumetinib.